Royal Bank of Canada
HRTX icon

Royal Bank of Canada’s Heron Therapeutics HRTX Stock Holding History

Royal Bank of Canada’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
143
-11,650
-99% -$13.5K ﹤0.01% 7373
2025
Q4 		$16K Buy
11,793
+5,832
+98% +$7.2K ﹤0.01% 6173
2025
Q3 		$8K Sell
5,961
-10,068
-63% -$16K ﹤0.01% 6567
2025
Q2 		$32K Buy
16,029
+5,133
+47% +$10.5K ﹤0.01% 6103
2025
Q1 		$24K Sell
10,896
-8,004
-42% -$15.5K ﹤0.01% 5855
2024
Q4 		$29K Buy
18,900
+432
+2% +$700 ﹤0.01% 5951
2024
Q3 		$36K Buy
18,468
+1,260
+7% +$3.01K ﹤0.01% 5847
2024
Q2 		$61K Buy
17,208
+5,172
+43% +$15.9K ﹤0.01% 5553
2024
Q1 		$34K Sell
12,036
-30,832
-72% -$77.5K ﹤0.01% 5695
2023
Q4 		$73K Buy
42,868
+27,647
+182% +$30.4K ﹤0.01% 5799
2023
Q3 		$16K Buy
15,221
+6,026
+66% +$8.58K ﹤0.01% 6256
2023
Q2 		$11K Sell
9,195
-2,355
-20% -$4.2K ﹤0.01% 6441
2023
Q1 		$18K Sell
11,550
-5,520
-32% -$13.8K ﹤0.01% 6061
2022
Q4 		$43K Buy
17,070
+10,993
+181% +$35.4K ﹤0.01% 5969
2022
Q3 		$25K Sell
6,077
-2,507
-29% -$9.81K ﹤0.01% 6052
2022
Q2 		$25K Sell
8,584
-22,244
-72% -$89.3K ﹤0.01% 6004
2022
Q1 		$176K Sell
30,828
-10,348
-25% -$75.7K ﹤0.01% 5200
2021
Q4 		$376K Buy
41,176
+14,059
+52% +$144K ﹤0.01% 4731
2021
Q3 		$290K Buy
27,117
+4,370
+19% +$53.2K ﹤0.01% 4809
2021
Q2 		$353K Sell
22,747
-1,835
-7% -$29.2K ﹤0.01% 4581
2021
Q1 		$398K Buy
24,582
+6,118
+33% +$109K ﹤0.01% 4377
2020
Q4 		$391K Sell
18,464
-1,231
-6% -$21.4K ﹤0.01% 4344
2020
Q3 		$292K Buy
19,695
+1,459
+8% +$22.8K ﹤0.01% 4266
2020
Q2 		$267K Sell
18,236
-5,724
-24% -$94K ﹤0.01% 4234
2020
Q1 		$281K Sell
23,960
-25,062
-51% -$471K ﹤0.01% 4080
2019
Q4 		$1.15M Buy
49,022
+31,282
+176% +$692K ﹤0.01% 3339
2019
Q3 		$329K Sell
17,740
-14,027
-44% -$258K ﹤0.01% 4115
2019
Q2 		$591K Buy
31,767
+19,290
+155% +$385K ﹤0.01% 3738
2019
Q1 		$305K Buy
12,477
+10,115
+428% +$265K ﹤0.01% 4081
2018
Q4 		$61K Sell
2,362
-1,684
-42% -$46.3K ﹤0.01% 4991
2018
Q3 		$128K Buy
4,046
+1,450
+56% +$54K ﹤0.01% 4732
2018
Q2 		$100K Buy
2,596
+2,387
+1,142% +$76K ﹤0.01% 4806
2018
Q1 		$6K Sell
209
-3,720
-95% -$84.4K ﹤0.01% 5880
2017
Q4 		$71K Sell
3,929
-2,322
-37% -$37.9K ﹤0.01% 5003
2017
Q3 		$101K Buy
6,251
+6,072
+3,392% +$95.2K ﹤0.01% 5010
2017
Q2 		$2K Sell
179
-375,789
-100% -$5.44M ﹤0.01% 6270
2017
Q1 		$5.64M Sell
375,968
-36,493
-9% -$505K ﹤0.01% 1828
2016
Q4 		$5.4M Sell
412,461
-5,439
-1% -$85.3K ﹤0.01% 1902
2016
Q3 		$7.2M Buy
+417,900
New +$7.75M ﹤0.01% 1686
2016
Q2 		– Sell
-16
Closed – – 6432
2016
Q1 		$0 Sell
16
-158
-91% -$3.12K ﹤0.01% 6484
2015
Q4 		$5K Sell
174
-1,266
-88% -$33.9K ﹤0.01% 6155
2015
Q3 		$35K Buy
+1,440
New +$48K ﹤0.01% 5313

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Royal Bank of Canada's HRTX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Heron Therapeutics (HRTX) stake by 99% in Q1 2026, selling an estimated $13.5K and leaving 143 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7373.

Royal Bank of Canada first reported a position in HRTX in Q3 2015 and has held it in 42 quarters since. The position peaked at $7.2M in Q3 2016. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Royal Bank of Canada held 143 shares of Heron Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 11,650 Heron Therapeutics shares in Q1 2026, an estimated $13.5K.
  • Heron Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7373 holding.
  • Royal Bank of Canada first reported a position in Heron Therapeutics in Q3 2015 and has held it in 42 quarters since.
  • Royal Bank of Canada's Heron Therapeutics position peaked at $7.2M in Q3 2016.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.